刺五加对慢性阻塞性肺疾病患者肺功能康复的短期疗效观察

Acanthopanax Senticosus facilitates pulmonary rehabilitation in patients with chronic obstructive pulmonary disease

目的 探讨刺五加注射液是否有改善慢性阻塞性肺疾病 (COPD)患者肺通气功能的作用。方法 在刺五加注射液 5 0 0mg静脉滴注前后测定COPD患者肺通气功能 ;采取配对研究方法 ,随机将COPD临床稳定期患者分为A、B两组 ,其中A组用刺五加注射液 5 0 0mg ,静脉滴注 ,每天1次 ,B组不用刺五加注射液。结果 刺五加注射液滴注前后 (间隔 1.5～ 2小时 )测定的第一秒用力呼气量 (FEV1)分别为 1.5 1L± 0 .5 0L和 1.5 7L± 0 .5 4L( 11例 ,P >0 .695 ) ;经刺五加注射液治疗7天后 ,A组患者 ( 2 9例 )FEV1从 1.5 7L± 0 .3 4L增加至 2 .13L± 0 .42L ,用力呼气容积 (FVC)从 2 .5 4L± 0 .40L增加至 2 .88L± 0 .46L ;B组 ( 2 9例 )FEV1从 1.74L± 0 .3 7L增加至 2 .0 8L± 0 .3 4L ,FVC从 2 .94L± 0 .42L增加至 3 .0 7L± 0 .3 7L。两组患者的肺功能增幅比较 :FEV1,0 .5 6L± 0 .3 9L比 0 .3 4L± 0 .3 2L(P <0 .0 5 ) ;FVC ,0 .3 4L± 0 .3 5L比 0 .12L± 0 .3 9L(P <0 .0 1)。结论 刺五加注射液无直接支气管扩张作用 。

Objective To evaluate the effect of parenteral solution of Acanthopanax Senticosus (AS-PS) on pulmonary rehabilitation in patients with chronic obstructive pulmonary disease (COPD) during stationary phase of their illness.Methods This investigation was done in two steps:first,the rapid bronchodilative effect of AS-PS was tested by measuring forced expiratory volume in one second (FEV 1) before and after intravenous administration of 500 mg AS-PS;Then the effect of one week administration of AS-PS (500 mg,Qd) on pulmonary function was evaluated by randomized case control trial,with arm A received AS-PS and arm B received placebo.Results There was no immediate improvement in FEV 1 (1.51L±0.50L vs 1.57L±0.54L,paired t test,P>0.05) after one bolus of 500mg AS-PS administration.After 7 days (bronchodilators and steroids was suspended five days before),FEV 1 and forced vital capacity (FVC) in both arms was improved (FEV 1:from 1.57L±0.34L to 2.13L±0.42L in arm A,from 1.74L±0.37L to 2.08L±0.34 L in arm B;FVC:from 2.54±0.40L to 2.88L±0.46L in arm A,from 2.94L±0.42L to 3.07L±0.37L in arm B).However,the increment of FEV 1 and FVC in arm A is significant bigger than that in arm B (FEV 1: 0.56L±0.39L vs 0.34L±0.32L,FVC 0.34L±0.35L vs 0.12L± 0.39L,P<0.05).Conclusion Acanthopanax Senticosus facilitates pulmonary rehabilitation in patients with COPD.